title: Health-related quality of life of patients receiving low-toxicity immunosuppressive regimens: a substudy of the Symphony Study.
abstract: OBJECTIVE
  To evaluate health-related quality of life (HRQoL) in patients with different low-toxicity regimens posttransplantation.
  
  
  METHODS
  One hundred fifty-six patients were randomized to standard-dose cyclosporine A (CsA), mycophenolate mofetil, and corticosteroids or daclizumab induction, mycophenolate mofetil, and corticosteroids with a low dose of CsA, tacrolimus (Low-Tac), or sirolimus. SF-36 Health survey was completed at baseline, 3, 6, and 12 months.
  
  
  RESULTS
  There were no differences between groups in SF-36 at baseline or at month 12. Low-Tac showed higher scores at month 3 than standard-dose CsA and low dose of CsA. Patients with serum creatinine less than or equal to 1.5 mg/mL had better HRQoL at 6 and 12 months. Proportion of these patients was higher in Low-Tac at 6 months. Physical component summary of Patients increased during follow-up, but mental component summary did not. Patients with acute rejection showed lower mental component summary at 6 months.
  
  
  CONCLUSIONS
  No HRQoL differences were identified among groups, but the low-dose Tac group showed the fastest improvement.
authors.affiliation: Renal Transplant Unit, Hospital Clínico, Barcelona, Spain.
authors.forename: Federico
authors.initials: F
authors.lastname: Oppenheimer
authors.forename: Pablo
authors.initials: P
authors.lastname: Rebollo
authors.forename: Josep M
authors.initials: JM
authors.lastname: Grinyo
authors.forename: Francisco
authors.initials: F
authors.lastname: Ortega
authors.forename: Jaime
authors.initials: J
authors.lastname: Sanchez-Plumed
authors.forename: Miguel
authors.initials: M
authors.lastname: Gonzalez-Molina
authors.forename: Domingo
authors.initials: D
authors.lastname: Hernandez
authors.forename: Fernando
authors.initials: F
authors.lastname: Anaya
authors.forename: Henrik
authors.initials: H
authors.lastname: Ekberg
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D000077561:Daclizumab; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006304:Health Status; D006306:Health Surveys; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use* / Q000633:toxicity; D016030:Kidney Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D011788:Quality of Life; D013997:Time Factors
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D000077561:Daclizumab; D009173:Mycophenolic Acid